These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30385058)

  • 1. Estimating costs and health outcomes of publicly funded tick-born encephalitis vaccination: A cost-effectiveness analysis.
    Shedrawy J; Henriksson M; Hergens MP; Askling HH
    Vaccine; 2018 Nov; 36(50):7659-7665. PubMed ID: 30385058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Subsidized TBE vaccination appears cost-effective in a life-time perspective].
    Askling H; Shedrawy J; Henriksson M
    Lakartidningen; 2019 Jun; 116():. PubMed ID: 31192427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of tick-borne encephalitis vaccination in Slovenian adults.
    Smit R
    Vaccine; 2012 Sep; 30(44):6301-6. PubMed ID: 22885012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of a potential anti-tick vaccine with combined protection against Lyme borreliosis and tick-borne encephalitis in Slovenia.
    Mihajlović J; Hovius JWR; Sprong H; Bogovič P; Postma MJ; Strle F
    Ticks Tick Borne Dis; 2019 Jan; 10(1):63-71. PubMed ID: 30197268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tick borne encephalitis (TBE)-vaccination coverage and analysis of variables associated with vaccination, Sweden.
    Askling HH; Insulander M; Hergens MP; Leval A
    Vaccine; 2015 Sep; 33(38):4962-8. PubMed ID: 26207593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Willingness to Pay for Vaccination against Tick-Borne Encephalitis and Implications for Public Health Policy: Evidence from Sweden.
    Slunge D
    PLoS One; 2015; 10(12):e0143875. PubMed ID: 26641491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines for tick-borne diseases and cost-effectiveness of vaccination: a public health challenge to reduce the diseases' burden.
    Šmit R; Postma MJ
    Expert Rev Vaccines; 2016; 15(1):5-7. PubMed ID: 26559456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of a publicly funded hepatitis A travel vaccination program in Ontario, Canada.
    Ramsay LC; Anyiwe K; Li M; Macdonald L; Coyte PC; Sander B
    Vaccine; 2019 Mar; 37(11):1467-1475. PubMed ID: 30770225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Field effectiveness of vaccination against tick-borne encephalitis.
    Heinz FX; Holzmann H; Essl A; Kundi M
    Vaccine; 2007 Oct; 25(43):7559-67. PubMed ID: 17869389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of tick-borne encephalitis and vaccines: clinical and economical aspects.
    Šmit R; Postma MJ
    Expert Rev Vaccines; 2015 May; 14(5):737-47. PubMed ID: 25427237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High burden of tick-borne encephalitis in Slovenia--challenge for vaccination policy.
    Grgič-Vitek M; Klavs I
    Vaccine; 2011 Jul; 29(32):5178-83. PubMed ID: 21620916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-reported tick-borne encephalitis (TBE) vaccination coverage in Europe: Results from a cross-sectional study.
    Erber W; Schmitt HJ
    Ticks Tick Borne Dis; 2018 May; 9(4):768-777. PubMed ID: 29501619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
    Yang MC; Tan EC; Su JJ
    Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tick-borne encephalitis in children in Styria and Slovenia between 1980 and 2003.
    Zenz W; Pansi H; Zoehrer B; Mutz I; Holzmann H; Kraigher A; Berghold A; Spork D
    Pediatr Infect Dis J; 2005 Oct; 24(10):892-6. PubMed ID: 16220087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
    Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
    Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of a targeted age-based West Nile virus vaccination program.
    Shankar MB; Staples JE; Meltzer MI; Fischer M
    Vaccine; 2017 May; 35(23):3143-3151. PubMed ID: 28456529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the annual burden of tick-borne encephalitis to inform vaccination policy, Slovenia, 2009 to 2013.
    Fafangel M; Cassini A; Colzani E; Klavs I; Grgič Vitek M; Učakar V; Muehlen M; Vudrag M; Kraigher A
    Euro Surveill; 2017 Apr; 22(16):. PubMed ID: 28449731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A campaign to increase the vaccination rate in a highly endemic tick-borne encephalitis region of Slovenia.
    Košnik IG; Lah AK
    Vaccine; 2013 Jan; 31(5):732-4. PubMed ID: 23246549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five year follow-up after primary vaccination against tick-borne encephalitis in children.
    Wittermann C; Izu A; Petri E; Gniel D; Fragapane E
    Vaccine; 2015 Apr; 33(15):1824-9. PubMed ID: 25728316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.